Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVATE: PS101-Mediated ACT in Liver Metastasis
NCT04021277Phase 1Terminated
- Sponsor
- EXACT Therapeutics AS
- Start
- Sep 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of PS101 in solid tumor and colorectal cancer (CRC) (2 arms), sponsored by EXACT Therapeutics AS. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Number of patients with adverse events at 12 weeks and 1 more. Started Sep 2019; status: terminated.
02
Drugs
PS101
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04021277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021277.